{"id":39680,"date":"2026-08-31T09:58:00","date_gmt":"2026-08-31T07:58:00","guid":{"rendered":"https:\/\/ggba.swiss\/addex-therapeutics-extends-its-cash-runway-into-the-fourth-quarter-of-2027\/"},"modified":"2026-08-31T10:00:24","modified_gmt":"2026-08-31T08:00:24","slug":"addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/","title":{"rendered":"Addex Therapeutics prolonge sa tr\u00e9sorerie jusqu&rsquo;au quatri\u00e8me trimestre 2027"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.addextherapeutics.com\/\">Addex Therapeutics<\/a> a lev\u00e9 un produit brut de USD 2,8 millions via son programme at-the-market conclu avec la banque d&rsquo;investissement am\u00e9ricaine H.C. Wainwright &amp; Co. Cette vente prolonge la tr\u00e9sorerie de l&rsquo;entreprise jusqu&rsquo;au quatri\u00e8me trimestre 2027.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Fond\u00e9e en 2002 \u00e0 Gen\u00e8ve, Addex d\u00e9veloppe des modulateurs allost\u00e9riques \u00e0 petites mol\u00e9cules contre les troubles neurologiques. Son candidat principal, le dipraglurant, cible la r\u00e9cup\u00e9ration apr\u00e8s une l\u00e9sion c\u00e9r\u00e9brale, notamment \u00e0 la suite d&rsquo;un accident vasculaire c\u00e9r\u00e9bral ou d&rsquo;un traumatisme cr\u00e2nien.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L&rsquo;entreprise avait conclu cet accord at-the-market en janvier 2024, aux termes duquel H.C. Wainwright intervient comme agent de vente moyennant une commission de 3 pour cent sur le produit brut. Initialement plafonn\u00e9 \u00e0 USD 2,1 millions d&rsquo;American depositary shares, une participation dans une soci\u00e9t\u00e9 non am\u00e9ricaine d\u00e9tenue par une banque am\u00e9ricaine et accessible aux investisseurs am\u00e9ricains, le plafond a \u00e9t\u00e9 relev\u00e9 \u00e0 USD 3,3 millions en d\u00e9cembre 2025. Addex a d\u00e9sormais vendu 437&rsquo;869 American depositary shares, repr\u00e9sentant plus de 52 millions d&rsquo;actions ordinaires. Le nombre total d&rsquo;actions \u00e9mises est rest\u00e9 inchang\u00e9, \u00e0 un peu plus de 218,5 millions, tandis que les actions en circulation sont pass\u00e9es \u00e0 plus de 210 millions.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L&rsquo;entreprise s&rsquo;est \u00e9galement montr\u00e9e active au-del\u00e0 de son propre pipeline, ayant lanc\u00e9 la <a href=\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-lance-la-spin-off-neurosterix-a-geneve-avec-un-investissement-de-usd-63-millions\/\">spin-off genevoise Neurosterix<\/a> et men\u00e9 un <a href=\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-mene-un-investissement-de-chf-2-millions-dans-stalicla\/\">investissement dans Stalicla<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Addex Therapeutics, la biotech genevoise de stade clinique d\u00e9veloppant des modulateurs allost\u00e9riques \u00e0 petites mol\u00e9cules contre les troubles neurologiques, a lev\u00e9 un produit brut de USD 2,8 millions via son programme at-the-market.<\/p>\n","protected":false},"author":6,"featured_media":39677,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1239,1171],"class_list":["post-39680","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-neuroscience-fr-2","tag-pharma-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Addex Therapeutics prolonge sa tr\u00e9sorerie jusqu&#039;en 2027 | GGBa<\/title>\n<meta name=\"description\" content=\"Addex Therapeutics l\u00e8ve USD 2,8 millions via son programme at-the-market, prolongeant sa tr\u00e9sorerie jusqu&#039;au quatri\u00e8me trimestre 2027.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Addex Therapeutics prolonge sa tr\u00e9sorerie jusqu&#039;en 2027 | GGBa\" \/>\n<meta property=\"og:description\" content=\"Addex Therapeutics l\u00e8ve USD 2,8 millions via son programme at-the-market, prolongeant sa tr\u00e9sorerie jusqu&#039;au quatri\u00e8me trimestre 2027.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-31T07:58:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-31T08:00:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Addex-Therapeutics-Modulation-1180x811-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Addex Therapeutics prolonge sa tr\u00e9sorerie jusqu&rsquo;au quatri\u00e8me trimestre 2027\",\"datePublished\":\"2026-08-31T07:58:00+00:00\",\"dateModified\":\"2026-08-31T08:00:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/\"},\"wordCount\":242,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Addex-Therapeutics-Modulation-1180x811-1.png\",\"keywords\":[\"Biotech\",\"Financing\",\"Neuroscience\",\"Pharma\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/\",\"name\":\"Addex Therapeutics prolonge sa tr\u00e9sorerie jusqu'en 2027 | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Addex-Therapeutics-Modulation-1180x811-1.png\",\"datePublished\":\"2026-08-31T07:58:00+00:00\",\"dateModified\":\"2026-08-31T08:00:24+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Addex Therapeutics l\u00e8ve USD 2,8 millions via son programme at-the-market, prolongeant sa tr\u00e9sorerie jusqu'au quatri\u00e8me trimestre 2027.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Addex-Therapeutics-Modulation-1180x811-1.png\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Addex-Therapeutics-Modulation-1180x811-1.png\",\"width\":1180,\"height\":811,\"caption\":\"Addex Therapeutics d\u00e9veloppe des modulateurs allost\u00e9riques \u00e0 petites mol\u00e9cules contre les troubles neurologiques, son candidat principal ciblant la r\u00e9cup\u00e9ration apr\u00e8s une l\u00e9sion c\u00e9r\u00e9brale.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Addex Therapeutics prolonge sa tr\u00e9sorerie jusqu&#8217;au quatri\u00e8me trimestre 2027\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Addex Therapeutics prolonge sa tr\u00e9sorerie jusqu'en 2027 | GGBa","description":"Addex Therapeutics l\u00e8ve USD 2,8 millions via son programme at-the-market, prolongeant sa tr\u00e9sorerie jusqu'au quatri\u00e8me trimestre 2027.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/","og_locale":"fr_FR","og_type":"article","og_title":"Addex Therapeutics prolonge sa tr\u00e9sorerie jusqu'en 2027 | GGBa","og_description":"Addex Therapeutics l\u00e8ve USD 2,8 millions via son programme at-the-market, prolongeant sa tr\u00e9sorerie jusqu'au quatri\u00e8me trimestre 2027.","og_url":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2026-08-31T07:58:00+00:00","article_modified_time":"2026-08-31T08:00:24+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Addex-Therapeutics-Modulation-1180x811-1.png","type":"image\/png"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Addex Therapeutics prolonge sa tr\u00e9sorerie jusqu&rsquo;au quatri\u00e8me trimestre 2027","datePublished":"2026-08-31T07:58:00+00:00","dateModified":"2026-08-31T08:00:24+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/"},"wordCount":242,"image":{"@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Addex-Therapeutics-Modulation-1180x811-1.png","keywords":["Biotech","Financing","Neuroscience","Pharma"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/","url":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/","name":"Addex Therapeutics prolonge sa tr\u00e9sorerie jusqu'en 2027 | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Addex-Therapeutics-Modulation-1180x811-1.png","datePublished":"2026-08-31T07:58:00+00:00","dateModified":"2026-08-31T08:00:24+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Addex Therapeutics l\u00e8ve USD 2,8 millions via son programme at-the-market, prolongeant sa tr\u00e9sorerie jusqu'au quatri\u00e8me trimestre 2027.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Addex-Therapeutics-Modulation-1180x811-1.png","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2026\/08\/Addex-Therapeutics-Modulation-1180x811-1.png","width":1180,"height":811,"caption":"Addex Therapeutics d\u00e9veloppe des modulateurs allost\u00e9riques \u00e0 petites mol\u00e9cules contre les troubles neurologiques, son candidat principal ciblant la r\u00e9cup\u00e9ration apr\u00e8s une l\u00e9sion c\u00e9r\u00e9brale."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/addex-therapeutics-prolonge-sa-tresorerie-jusquau-quatrieme-trimestre-2027\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Addex Therapeutics prolonge sa tr\u00e9sorerie jusqu&#8217;au quatri\u00e8me trimestre 2027"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/39680","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=39680"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/39680\/revisions"}],"predecessor-version":[{"id":39682,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/39680\/revisions\/39682"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/39677"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=39680"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=39680"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=39680"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}